Accéder au contenu
Merck

Down-regulation and aberrant cytoplasmic expression of GLTSCR2 in prostatic adenocarcinomas.

Cancer letters (2013-08-08)
Jee-Youn Kim, Young-Eun Cho, Gou Young Kim, Hyung-Lae Lee, Sun Lee, Jae-Hoon Park
RÉSUMÉ

GLTSCR2 is a nuclear/nucleolar protein that translocates to the nucleoplasm, suppressed and mutated in human cancers. Our aim in this study was to investigate whether downregulation or cytoplasmic expression of GLTSCR2 has any pathological significance in prostatic cancer development or progression. In this study we show that GLTSCR2 is suppressed in prostatic cancers and its expression is significantly associated with Gleason's scores. Furthermore, we investigated the pathogenetic mechanism of downregulation and cytoplasmic expression of GLTSCR2 in development or progression of prostatic cancers. Taken together, our results indicate that GLTSCR2 functions as a tumor suppressor in prostatic adenocarcinomas.